Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  alisertib
Find trials that include:  Any drugs shown
Results 1-15 of 15 for your search:
Start Over
Alisertib and Erlotinib Hydrochloride in Treating Patients with Recurrent Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TH-036, NCI-2011-03306, FER-TH-036, X14004, NCT01471964
Alisertib in Treating Patients with Malignant Mesothelioma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 2014-0497, NCI-2014-02568, X14024, NCT02293005
Alisertib in Combination with Cytarabine and Idarubicin in Treating Patients with High-Risk Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-334, NCI-2016-00332, NCT02560025
Combining MLN8237 with Nab-Paclitaxel in Patients with Advanced Solid Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201210123, NCI-2012-01611, NCT01677559
Alisertib, Bortezomib, and Rituximab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S12-02028, NCI-2012-01712, CDR0000740877, P9086, 9086, NCT01695941
Alisertib and Romidepsin in Treating Patients with Relapsed or Refractory B-Cell or T-Cell Lymphomas
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0602, NCI-2013-01272, TX035, 9342, NCT01897012
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#240, NCI-2013-01388, NCT01924260
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients with Recurrent High Grade Gliomas
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13P.528, NCI-2014-01344, 2013-12, 3007, NCT02186509
Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C14019, NCI-2014-01843, U1111-1155-6072, NCT02214147
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC GI1536, NCI-2014-02475, 9824, NCT02319018
A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Patients With Advanced Nonhematologic Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C28002, NCI-2015-01108, 2014-003340-12, U1111-1159-5831, NCT02327169
MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: C032-6001 (MLN1117-1003), NCI-2015-02103, 2015-001032-38, MLN1117-1003, REec-2016-2039, U1111-1166-8653, UTN, NCT02551055
Sapanisertib and Alisertib in Treating Patients with Incurable Refractory Solid Tumors or Metastatic Triple-Negative Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: 15-1135, NCI-2016-00443, NCT02719691
Alisertib in Treating Patients with Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 15H10, NCI-2015-01219, STU00200682, NCT02530619
Start Over